Case report: Acute renal injury as a result of liposomal amphotericin B treatment in sodium stibogluconate unresponsive visceral leishmaniasis
- PMID: 22144439
- PMCID: PMC3225147
- DOI: 10.4269/ajtmh.2011.11-0449
Case report: Acute renal injury as a result of liposomal amphotericin B treatment in sodium stibogluconate unresponsive visceral leishmaniasis
Abstract
We report an unusual case of visceral leishmaniasis occurring in a patient from Sichuan China. The patient presented with a remitting fever, anemia, and pancytopenia. The case was confirmed as visceral leishmaniasis by microscopical detection of the Leishmania species amastigote in bone marrow aspirate. The patient was treated with 10 mg/kg/day of sodium stibogluconate for 5 days, with no therapeutic response. As a result, the patient was treated with liposomal amphotericin B (LAB) at 10 mg/day as an initial dosage. After treatment with an increasing drug dosage for 7 days, acute renal injury was evident as indicated by increased serum creatinine and urea nitrogen. LAB administration was discontinued until serum creatinine and serum urea nitrogen regressed on Day 15. Two maintenance treatments of 100 mg/day LAB were given on Days 19 and 26 (total 870 mg, 14.5 mg/kg). Bone marrow aspirate and clinical examination suggested total remission.
Figures
Similar articles
-
Magnitude of unresponsiveness to sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar.Natl Med J India. 2005 May-Jun;18(3):131-3. Natl Med J India. 2005. PMID: 16130613
-
[A case of antimony resistant kala-azar cured with amphotericin B].Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi. 2007 Jun;25(3):inside front page. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi. 2007. PMID: 18038767 Chinese. No abstract available.
-
[Treatment of visceral leishmaniasis in children].Med Trop (Mars). 2007 Feb;67(1):73-8. Med Trop (Mars). 2007. PMID: 17506279 Review. French.
-
Cure of antimony-unresponsive Indian visceral leishmaniasis with amphotericin B lipid complex.J Infect Dis. 1996 Mar;173(3):762-5. doi: 10.1093/infdis/173.3.762. J Infect Dis. 1996. PMID: 8627049 Clinical Trial.
-
Liposomal amphotericin B in the treatment of visceral leishmaniasis in immunocompetent patients.Fundam Clin Pharmacol. 2003 Apr;17(2):183-8. doi: 10.1046/j.1472-8206.2003.00168.x. Fundam Clin Pharmacol. 2003. PMID: 12667228 Review.
Cited by
-
A link between circulating immune complexes and acute kidney injury in human visceral leishmaniasis.Sci Rep. 2024 Apr 30;14(1):9870. doi: 10.1038/s41598-024-60209-0. Sci Rep. 2024. PMID: 38684845 Free PMC article.
References
-
- Zhang LP, Zhang FN. Epidemiological and clinical analysis of 166 kala-azar cases. Parasites Infect Dis. 2010;18:181–186.
-
- Mondal S, Bhattacharya P, Ali N. Current diagnosis and treatment of visceral leishmaniasis. Expert Rev Anti Infect Ther. 2010;8:919–944. - PubMed
-
- Sundar S, Sinha PK, Rai M, Verma DK, Nawin K, Alam S, Chakravarty J, Vaillant M, Verma N, Pandey K, Kumari P, Lal CS, Arora R, Sharma B, Ellis S, Strub-Wourgaft N, Balasegaram M, Olliaro P, Das P, Modabber F. Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomized controlled trial. Lancet. 2011;377:477–486. - PubMed
-
- Kang X, Liu Y, Liu K, Lu X. Human leishmaniasis: a retrospective clinical analysis of 86 patients. Chin J Infect Chemother. 2009;9:241–243.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous